Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea

Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching P, Vachon C, Ganz PA (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Journal of the National Cancer Institute Oxford University Press

Book Volume: 113

Pages Range: 1105-1108

Journal Issue: 8

DOI: 10.1093/jnci/djaa160

Abstract

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Mayo Clinic US United States (USA) (US) Dana–Farber Cancer Institute US United States (USA) (US) University of Pittsburgh US United States (USA) (US) Kaiser Permanente US United States (USA) (US) Brigham and Women's Hospital (BWH) US United States (USA) (US) University of California Los Angeles (UCLA) US United States (USA) (US)

How to cite

APA:

Ruddy, K.J., Schaid, D.J., Batzler, A., Cecchini, R.S., Partridge, A.H., Norman, A.,... Ganz, P.A. (2021). Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 113(8), 1105-1108. https://doi.org/10.1093/jnci/djaa160

MLA:

Ruddy, Kathryn J., et al. "Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea." Journal of the National Cancer Institute 113.8 (2021): 1105-1108.

BibTeX: Download